Chang H, et al. - Among 959 patients diagnosed with TxN2-3M0 nasopharyngeal carcinoma (NPC) and treated with neoadjuvant chemotherapy (NACT) of 3-4 cycles and intensity-modulated radiotherapy (IMRT), researchers assessed the value of concurrent chemotherapy (CCT). Using a series of clinical features (age, gender, T stage, N stage, NACT regimen, and Epstein-barr virus DNA) as covariates, they performed propensity score matching between patients treated with and without CCT (called the CCT and non-CCT groups, respectively). More acute toxicities were reported in relation to the use of CCT, although it offered survival benefit to N2-3 NPC patients treated with NACT of ≥3 cycles and IMRT. Caution should be exercised while using it in these patients.